Tisotumab vedotin shows clinically meaningful OS improvement versus chemo for metastatic cervical cancer

Prof Ignace Vergote - UZ Leuven, Leuven, Belgium
Tisotumab vedotin shows clinically meaningful OS improvement versus chemo for metastatic cervical cancer ( Prof Ignace Vergote - UZ Leuven, Leuven, Belgium )
7 Nov 2023

Pembrolizumab plus chemoradiotherapy shows clinically meaningful improvement in PFS for locally advanced cervical cancer

Prof Domenica Lorusso - Fondazione IRCCS National Cancer Institute, Milan, Italy
Pembrolizumab plus chemoradiotherapy shows clinically meaningful improvement in PFS for locally advanced cervical cancer ( Prof Domenica Lorusso - Fondazione IRCCS National Cancer Institute, Milan, Italy )
7 Nov 2023

Gynaecological Cancers

Dr Susana Banerjee - The Royal Marsden NHS Foundation Trust, London, UK
Gynaecological Cancers ( Dr Susana Banerjee - The Royal Marsden NHS Foundation Trust, London, UK )
7 Nov 2023

Atezolizumab with platinum-based CT and niraparib show no improvement in survival for rOC

Dr Antonio Gonzalez Martin - Cancer Center Clínica Universidad de Navarra, Madrid, Spain
Atezolizumab with platinum-based CT and niraparib show no improvement in survival for rOC ( Dr Antonio Gonzalez Martin - Cancer Center Clínica Universidad de Navarra, Madrid, Spain )
31 Oct 2023

Induction chemotherapy added to chemoradiation improves PFS and OS in advanced cervical cancer

Dr Mary McCormack - University College Hospital, London, UK
Induction chemotherapy added to chemoradiation improves PFS and OS in advanced cervical cancer ( Dr Mary McCormack - University College Hospital, London, UK )
23 Oct 2023

Durvalumab addition to chemo shows endometrial cancer benefit

Prof Shannon Westin - University of Texas MD Anderson Cancer Center, Houston, USA
Durvalumab addition to chemo shows endometrial cancer benefit ( Prof Shannon Westin - University of Texas MD Anderson Cancer Center, Houston, USA )
21 Oct 2023

Part 6: Which different PARP inhibitors are available

Prof Philip Cornford - Royal Liverpool University Hospital, Liverpool, UK
Part 6: Which different PARP inhibitors are available ( Prof Philip Cornford - Royal Liverpool University Hospital, Liverpool, UK )
5 Sep 2023

Part 7: Similarities and Differences

Prof Philip Cornford - Royal Liverpool University Hospital, Liverpool, UK
Part 7: Similarities and Differences ( Prof Philip Cornford - Royal Liverpool University Hospital, Liverpool, UK )
5 Sep 2023

Part 8: How PARP inhibitors are being used now

Prof Philip Cornford - Royal Liverpool University Hospital, Liverpool, UK
Part 8: How PARP inhibitors are being used now ( Prof Philip Cornford - Royal Liverpool University Hospital, Liverpool, UK )
5 Sep 2023

Part 9: What PARP inhibitors mean for the future and what to look out for

Prof Philip Cornford - Royal Liverpool University Hospital, Liverpool, UK
Part 9: What PARP inhibitors mean for the future and what to look out for ( Prof Philip Cornford - Royal Liverpool University Hospital, Liverpool, UK )
5 Sep 2023

The case for investing in women's cancers in Asia Pacific

Dr Heather White - Executive Director, TogetHER for Health
The case for investing in women's cancers in Asia Pacific ( Dr Heather White - Executive Director, TogetHER for Health )
4 Sep 2023

Nigeria solidarity support fund and the annual youth engagement campaign on HPV

Dr Fejiro Chinye-Nwoko - CEO, Nigeria Solidarity Support Fund, Lagos, Nigeria
Nigeria solidarity support fund and the annual youth engagement campaign on HPV ( Dr Fejiro Chinye-Nwoko - CEO, Nigeria Solidarity Support Fund, Lagos, Nigeria )
25 Aug 2023